Home Cart Sign in  
Chemical Structure| 656820-32-5 Chemical Structure| 656820-32-5

Structure of Reversine
CAS No.: 656820-32-5

Chemical Structure| 656820-32-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Reversine, a synthetic purine analogue(2,6-disubstituted purine), is a potent human A3 adenosine receptor antagonist with Ki of 0.66 μM, and a pan-aurora A/B/C kinase inhibitor with IC50 of 12 nM/13 nM/20 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Reversine

CAS No. :656820-32-5
Formula : C21H27N7O
M.W : 393.49
SMILES Code : C12=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC(NC5CCCCC5)=C1N=CN2
MDL No. :MFCD09953189
InChI Key :ZFLJHSQHILSNCM-UHFFFAOYSA-N
Pubchem ID :210332

Safety of Reversine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Reversine

epigenetics
DNA
GPCR

Isoform Comparison

Biological Activity

Target
  • Aurora A

    Aurora A, IC50:12 nM

  • Aurora B

    Aurora B, IC50:13 nM

  • Aurora C

    Aurora C, IC50:20 nM

  • Adenosine Receptor

    human A3 adenosine receptor, Ki:0.66 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
ANJEA-CD 5 µM 30 minutes Inhibit ANJEA kinase activity Plant Biotechnol J. 2023 Jan;21(1):63-77.
FER-CD 5 µM 30 minutes Inhibit FER kinase activity Plant Biotechnol J. 2023 Jan;21(1):63-77.
HERK1-CD 5 µM 30 minutes Inhibit HERK1 kinase activity Plant Biotechnol J. 2023 Jan;21(1):63-77.
THE1-CD 5 µM 30 minutes Inhibit THE1 kinase activity Plant Biotechnol J. 2023 Jan;21(1):63-77.
DDX11/C0 cells 100 nM 1 day Reversine accelerated mitosis, reducing APC3 knockdown-induced cell death and spindle checkpoint-dependent arrest. Nat Commun. 2015 Oct 1;6:8399.
OC2 cells 1 µM 12 hours To evaluate the effect of Reversine on OC2 cell growth, results showed that Reversine significantly suppressed cell proliferation. J Biomed Sci. 2012 Jan 27;19(1):9.
OCSL cells 1 µM 12 hours To evaluate the effect of Reversine on OCSL cell growth, results showed that Reversine significantly suppressed cell proliferation. J Biomed Sci. 2012 Jan 27;19(1):9.
Bovine ear marginal tissue fibroblasts 20 nM 2 days Reversine-treated fibroblasts acquired the differentiation potential for neural lineage under neural-inducing (NID) conditions and expressed neural-specific markers. Int J Biol Sci. 2016 Jan 1;12(1):53-62.
HCT116 colon cancer cells 1 µM 24 hours To investigate the effect of Reversine on caspase-2 activity in HCT116 cells, the results showed that Reversine induced caspase-2 activation and led to the cleavage of MDM-2 protein. Cell Death Differ. 2019 Dec;26(12):2695-2709.
C2C12 myoblasts 20 nM 4 days Inhibits the differentiation of C2C12 myoblasts, preventing myotube formation, and increases their plasticity, allowing them to differentiate into osteoblasts and adipocytes under specific inducing conditions. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10482-7.
3T3E1 osteoblasts 300 nM 4 days Increases the plasticity of 3T3E1 osteoblasts, allowing them to differentiate into adipocytes under adipocyte-inducing conditions. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10482-7.
Human primary skeletal myoblasts 300 nM 4 days Increases the plasticity of human primary skeletal myoblasts, allowing them to differentiate into osteoblasts and adipocytes under specific inducing conditions. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10482-7.
Bovine ear marginal tissue fibroblasts 5 µM 4 days Reversine-treated fibroblasts acquired a drastically different morphology, transformed from spindle shape into considerably larger in size, flatter, and more adhesive to the culture plate, and displayed marked cell swelling and polyploid cell formation. Int J Biol Sci. 2016 Jan 1;12(1):53-62.
CHO cells 1000 nM 48 hours Reversine combined with PTX significantly improved micronucleation efficiency in CHO cells and reduced cytotoxicity. Nucleic Acids Res. 2024 Feb 9;52(3):1498-1511.
HFL1-iPS cells 1000 nM 48 hours Reversine combined with PTX significantly improved micronucleation efficiency in HFL1-iPS cells and reduced cytotoxicity. Nucleic Acids Res. 2024 Feb 9;52(3):1498-1511.
MCF-7 cells 5 µM 48 hours Reversine inhibited MCF-7 cell proliferation, particularly at the tumor-stroma interface, but no additional anti-proliferative effect was observed in the bulk region. Nat Commun. 2014 Dec 9;5:5662.
Mouse embryo cells 0.5 µM 8- to 16-cell division Observe chromosome segregation errors, found that 48% of reversine-treated blastomeres exhibited lagging chromosomes and micronuclei formation during mitosis Nat Commun. 2016 Mar 29;7:11165.
Mouse embryo cells 0.5 µM four- to eighourst-cell division Induce chromosome segregation errors, generate aneuploid cells, resulting in embryo death during peri-implantation development Nat Commun. 2016 Mar 29;7:11165.
Mouse pre-implantation embryos 0.5 µM four- to eighourst-cell division stage Induced chromosome segregation errors, generating aneuploid cells and leading to embryo death during peri-implantation development. Nat Commun. 2016 Mar 29;7:11165.
HeLa cells 0.5 µM Inhibits MPS1 autophosphorylation, causing chromosome alignment defects, but does not affect P-S10-H3 levels J Cell Biol. 2010 Jul 12;190(1):73-87.
HeLa cells 1 µM Completely overrides the spindle checkpoint in the presence of 3.3 µM nocodazole, causing MAD1 and the RZZ complex to fail to localize to kinetochores J Cell Biol. 2010 Jul 12;190(1):73-87.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD/SCID mice MCF-7 breast cancer model Intraperitoneal injection 0.5 mg/kg Twice a week for 8 weeks Reversine treatment inhibited MCF-7 tumor growth and bone metastasis, reducing tumor stromalization including collagen deposition and recruitment of activated stromal cells. Nat Commun. 2014 Dec 9;5:5662.
Mice Chromosome mosaicism model In embryo culture medium 0.5 mM Four- to eight-cell division stage, followed by culture in inhibitor-free medium until the mature blastocyst stage To investigate the fate of aneuploid cells and the developmental potential of mosaic embryos, it was found that mosaic embryos have full developmental potential provided they contain sufficient euploid cells. Nat Commun. 2016 Mar 29;7:11165.
Mice Chromosome mosaicism model In vitro culture 0.5 mM Four- to eight-cell division Investigate the fate of aneuploid cells and the developmental potential of mosaic embryos, found that reversine-treated embryos died during early postimplantation stages, but mosaic embryos containing sufficient normal euploid cells have full developmental potential Nat Commun. 2016 Mar 29;7:11165.
SCID/Beige mice Model of diffuse MM lesions Intravenous injection 1 mg/kg Twice weekly Reversine significantly reduced tumor burden in the diffuse myeloma bone lesion model Nat Med. 2010 Apr;16(4):483-9
Arabidopsis Arabidopsis seedlings Root treatment 5 μM 24 hours Enhanced innate immunity in plant roots and thus alleviated soil-borne diseases Plant Biotechnol J. 2023 Jan;21(1):63-77.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.54mL

0.51mL

0.25mL

12.71mL

2.54mL

1.27mL

25.41mL

5.08mL

2.54mL

References

 

Historical Records

Categories